Caren L D, Billett J N, Mandel A D
Toxicol Lett. 1985 Jan;24(1):91-7. doi: 10.1016/0378-4274(85)90145-6.
Mice were treated for 7 weeks with doses of methyldopa somewhat exceeding those given to man, and mixed immunotoxic effects were observed. Daily subcutaneous injections of 5 mg (in 0.1 ml) methyldopa or saline (0.1 ml) did not generally alter body weights, except on day 19, when the methyldopa-treated mice weighed significantly less. During treatment, all mice were immunized twice with sheep red blood cells (SRBC) and bled four times. Anti-SRBC titers were not affected by methyldopa treatment, but leukocyte counts were dramatically decreased, and hematocrits to a lesser degree. Although in methyldopa-treated mice spleen and kidneys were increased in size, liver, lung, heart, and thymus size was not affected. These results are discussed in the context of other studies on the mode of action of methyldopa in eliciting an autoimmune anemia in man treated therapeutically with this drug.
用略高于人体用药剂量的甲基多巴对小鼠进行7周治疗后，观察到了混合免疫毒性作用。每日皮下注射5毫克（溶于0.1毫升）甲基多巴或生理盐水（0.1毫升），一般不会改变体重，但在第19天时，接受甲基多巴治疗的小鼠体重明显较轻。治疗期间，所有小鼠均用绵羊红细胞（SRBC）免疫两次，并采血四次。抗SRBC滴度不受甲基多巴治疗的影响，但白细胞计数显著降低，血细胞比容降低程度较小。虽然接受甲基多巴治疗的小鼠脾脏和肾脏体积增大，但肝脏、肺、心脏和胸腺的大小未受影响。结合其他关于甲基多巴作用模式的研究，对这些结果进行了讨论，这些研究涉及甲基多巴在接受该药物治疗的人类中引发自身免疫性贫血的情况。
